SAB Biotherapeutics (NASDAQ:SABS) Earns “Buy” Rating from Chardan Capital
SAB Biotherapeutics (NASDAQ:SABS – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at Chardan Capital in a research note issued on Thursday,Benzinga reports. They presently have a $20.00 price target on the stock. Separately, HC Wainwright initiated coverage on SAB Biotherapeutics in a research note on Wednesday. They issued a “buy” rating […]
SAB Biotherapeutics (NASDAQ:SABS – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at Chardan Capital in a research note issued on Thursday,Benzinga reports. They presently have a $20.00 price target on the stock. Separately, HC Wainwright initiated coverage on SAB Biotherapeutics in a research note on Wednesday. They issued a “buy” rating […]
